1. Metabolic Enzyme/Protease Cell Cycle/DNA Damage JAK/STAT Signaling Protein Tyrosine Kinase/RTK PI3K/Akt/mTOR Anti-infection Apoptosis
  2. HSP EGFR Akt Dengue Virus Caspase
  3. HS-72

HS-72 is a selective allosteric inducible heat shock protein 70 Hsp70i inhibitor. HS-72 reduces ATP affinity of Hsp70i, elevates caspase 3/7 apoptotic activity, and promotes degradation of Hsp70 client proteins, including HER2 and Akt, and blocks DENV entry by disrupting Hsp70i association with the DENV receptor complex. HS-72 can be used for breast cancer and dengue virus infection research.

For research use only. We do not sell to patients.

HS-72

HS-72 Chemical Structure

CAS No. : 1118861-60-1

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

HS-72 is a selective allosteric inducible heat shock protein 70 Hsp70i inhibitor. HS-72 reduces ATP affinity of Hsp70i, elevates caspase 3/7 apoptotic activity, and promotes degradation of Hsp70 client proteins, including HER2 and Akt, and blocks DENV entry by disrupting Hsp70i association with the DENV receptor complex. HS-72 can be used for breast cancer and dengue virus infection research[1][2].

IC50 & Target[1][2]

Hsp70i

 

Caspase 3

 

Caspase 7

 

Akt

 

HER2

 

DENV

 

In Vitro

HS-72 acts as an allosteric inhibitor of Hsp70i. It only reduces the ATP-binding affinity of Hsp70i without inhibiting its intrinsic ATPase activity, and can induce conformational rearrangement of purified Hsp70 protein[1].
HS-72 (0.001-0.1 mM) was identified via FLECS chemoproteomic screening. Biochemical tests including affinity pull-down, thermofluor melting assay and limited proteolysis-mass spectrometry verify that HS-72 selectively binds Hsp70i over constitutive Hsc70, while Hsp90 recovery is considered nonspecific in the affinity-resin assay[1].
HS-72 (25, 50 μM; 48-72 h) inhibits proliferation of BT474, MCF-7 and SkBr3 breast cancer cells, while non-tumorigenic MCF10A and RWPE1 cells are relatively insensitive to HS-72[1].
HS-72 (1-100 μM; 24 h) dose-dependently elevates caspase 3/7 apoptotic activity in BT474, HeLa, HepG2, T47D and LNCaP tumor cell lines[1].
HS-72 (10, 50 μM; 24 h) promotes degradation of Hsp70 client proteins HER2 and Akt in BT474 and MCF-7 breast cancer cells, and shows stronger degradation activity when combined with HS-10[1].
HS-72 (50, 100 μM; 18 h) induces accumulation of insoluble mutant HttQ74-GFP aggregates in PC12 neuronal cells[1].
HS-72 (50-100 nmol/mL; 1 h pretreatment; 24 h post-infection) dose-dependently reduces DENV infection in U937+DC-SIGN cells while maintaining cell viability at concentrations below 90 nmol/mL[2].
HS-72 reduces infectious DENV production in a foci forming assay, with an EC50 of 22.8 nmol/mL[2].
HS-72 (75 nmol/mL) inhibits DENV infection at the early stage of the viral life cycle, and significantly reduces viral RNA at the entry stage in U937+DC-SIGN cells[2].
HS-72 (75 nmol/mL; 1 h pretreatment) disrupts the in situ interactions of Hsp70i with DENV E protein and DC-SIGN at 4 h post-infection, indicating inhibition of Hsp70i association with the DENV receptor complex[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: BT474, MCF-7, SkBr3
Concentration: 25, 50 μM
Incubation Time: 48, 72 h
Result: Inhibited proliferation of BT474, MCF-7 and SkBr3 breast cancer cells.
Non-tumorigenic MCF10A and RWPE1 cells were relatively insensitive under the same experimental context.

Apoptosis Analysis[1]

Cell Line: BT474, HeLa, HepG2, T47D, LNCaP
Concentration: 1, 10, 25, 50, 100 μM
Incubation Time: 24 h
Result: Elevated caspase 3/7 activity in a dose-dependent manner in all tested tumor cell lines.

Western Blot Analysis[1]

Cell Line: BT474, MCF-7
Concentration: 10, 50 μM
Incubation Time: 24 h
Result: Single drug treatment promoted the degradation of Hsp70 client proteins HER2 and Akt in BT474 and MCF-7 cells.
Combined HS-10 drug administration exerted stronger degradation effects on HER2 and Akt than single-drug monotherapy.

Cell Viability Assay[1]

Cell Line: U937+DC-SIGN
Concentration: 50, 70, 80, 90, 100 nmol/mL
Incubation Time: 1 h pretreatment; 24 h post-infection
Result: Reduced the percentage of DENV-infected cells in a dose-dependent manner.
DENV infection resulted in 56% infected cells in the control group, while HS-72 reduced infection to 34%, 15%, 9%, 6% and 4% at 50, 70, 80, 90 and 100 nmol/mL, respectively.
Cell viability was maintained at concentrations below 90 nmol/mL.

Real Time qPCR[1]

Cell Line: U937+DC-SIGN
Concentration: 75 nmol/mL
Incubation Time: 1 h pretreatment; 1 h attachment at 4°C; 1 h entry at 37°C
Result: Inhibited DENV infection at the entry stage.
Significantly reduced viral RNA during the entry stage according to qPCR analysis, while the time-of-addition assay showed that HS-72 was effective when added before infection, at infection, or 1 h post-infection.
Parmacokinetics
Species Dose Route T1/2
Mice[1] 20 mg/kg i.p. 0.4 h
In Vivo

HS-72 (1-30 mg/kg; i.p.; twice a week; for 60 days) causes no obvious body weight loss or lethal toxicity in wild-type FVB female mice[1].
HS-72 (20 mg/kg; i.p.; twice a week; for 2 days of administration, blood sampling on day 5) induces no abnormal hematological, hepatic and renal biochemical parameters in wild-type FVB female mice [1].
HS-72 (20 mg/kg; i.p.; twice a week; for 21 days) inhibits tumor growth in a HER2-overexpressing MMTV-neu spontaneous breast tumor mouse model[1].
HS-72 (20 mg/kg; i.p.; twice a week or once daily) prolongs median survival in a HER2-overexpressing MMTV-neu spontaneous breast tumor mouse model; twice-weekly dosing prolongs median survival by 6 days, and once-daily dosing prolongs median survival by 13 days[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wild-type FVB female mice[1]
Dosage: 1, 5, 10, 20, 30 mg/kg
Administration: Intraperitoneal injection (i.p.); twice a week; for 60 days
Result: No obvious body weight loss or lethal toxicity was observed across all tested dosage groups during the whole administration cycle.
Animal Model: Wild-type FVB female mice[1]
Dosage: 20 mg/kg
Administration: Intraperitoneal injection (i.p.); injected on day 1 and day 4; blood samples collected on day 5
Result: Complete blood count, liver and renal function indicators showed no significant differences from untreated control mice.
Animal Model: HER2-overexpressing MMTV-neu spontaneous breast tumor mouse model[1]
Dosage: 20 mg/kg
Administration: Intraperitoneal injection (i.p.); twice weekly; for 21 days
Result: Was well tolerated in vivo.
Inhibited tumor growth in the HER2-overexpressing MMTV-neu spontaneous breast tumor model after twice-weekly administration for 21 days.
Animal Model: HER2-overexpressing MMTV-neu spontaneous breast tumor mouse model survival assay[1]
Dosage: 20 mg/kg
Administration: Intraperitoneal injection (i.p.); twice a week or once daily
Result: Prolonged median survival compared with untreated animals.
Twice-weekly dosing prolonged median survival by 6 days.
Once-daily dosing prolonged median survival by 13 days.
Molecular Weight

364.44

Formula

C20H24N6O

CAS No.
SMILES

O=C(NC1=NC2=CC=CC=C2N1CCC)C3CN(CCC3)C4=NC=CN=C4

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
HS-72
Cat. No.:
HY-117252
Quantity:
MCE Japan Authorized Agent: